
Sign up to save your podcasts
Or


In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib?
By Bernard Marini, Anthony Perissinotti, et al.4.5
2828 ratings
In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib?

498 Listeners

28 Listeners

184 Listeners

8,187 Listeners

2 Listeners

756 Listeners

12 Listeners

53 Listeners

57 Listeners

136 Listeners

1 Listeners

49 Listeners

185 Listeners

43 Listeners

3 Listeners